Natera

10/20/2026

In observance of Pregnancy and Infant Loss Awareness Month, Dr. Shahin Ghadir, Reproductive Endocrinology & Infertility Specialist, shares what patients should know after experiencing pregnancy loss.

Shahin Ghadir, MD, FACOG

10/19/2026

At this year’s European Society for Medical Oncology (ESMO) Annual Congress, we’re sharing exciting progress in precision oncology. Twenty abstracts, including four rapid oral presentations, feature Natera technology across multiple tumor types and treatment modalities.

Learn more about our expanding diagnostics portfolio on our website and connect with us at booth 1015 during the meeting.

https://ow.ly/xoOl50ZZ7Wx

Natera and collaborators are presenting 20 abstracts and showcasing an expanded precision diagnostics portfolio, redefining how cancer is tracked at the molecular level.

10/15/2026

We’re honored to share that our Signatera™ test has been named to TIME's Best Inventions of 2026 list. The annual list features life-changing innovations evaluated on originality, efficacy, ambition, and impact.

Signatera is a personalized, molecular residual disease (MRD) test for patients diagnosed with cancer. Built from the unique genomic signature of each patient’s tumor, Signatera detects and quantifies tiny fragments of circulating tumor DNA (ctDNA) in the blood, providing ongoing monitoring for disease recurrence and response to treatment across cancer types. The test also plays an important role in oncology drug development, helping pharmaceutical companies identify patients for clinical trials and accelerate the approval of novel therapies.

Read more: https://ow.ly/aVp750ZY1B7

Find out why Natera Signatera is on TIME's list of 2026's best inventions.

10/13/2026

Chance Osborne, marketing manager on our oncology patient engagement team and triple negative breast cancer survivor, recently shared her story with USA TODAY, including how she uses Signatera™ every three months to monitor her health in survivorship.

Thank you, Chance, for your openness and for inspiring others this Breast Cancer Awareness Month. 💗

https://ow.ly/unMz50ZWYWy

10/12/2026

Today we are shining a light on Matt Moyer. Matt is a staff biostatistician at Natera, where he designs rigorous validation studies to support our growing product portfolio. His work focuses on tests within organ health and women’s health.

For Matt, this work hits close to home. While researching Natera during the interview process in 2021, he discovered Prospera™ Kidney and thought there should be a test like this for lung transplant patients, like his mom. He then learned that the development of Prospera™ Lung was underway, and his first project became its validation. When he shared his family's story, a colleague captured the team's commitment perfectly: “We have to get this right for Matt's mom.”

10/09/2026

Fortune's “Future 120” list has just been released and we’re honored to be recognized. This list highlights companies across industries poised to define the next chapter of business and innovation.

Every day, our team is focused on advancing the technology and solutions to support the patients who need it most.

https://ow.ly/CWsa50ZWx23

10/09/2026

Four of our abstracts were selected for oral presentations at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting, showcasing the expanding clinical utility of Signatera™ across tumor types and treatment settings.
Learn more about our latest data: https://ow.ly/UxOF50ZWw7S

10/08/2026

Natera is proud to be the 2026 Premier National Series Sponsor of the Susan G. Komen Race for the Cure® and MORE THAN PINK Walk® events.

So far, we’ve walked with you at the:
📍 Komen Seattle MORE THAN PINK Walk
📍 Komen Omaha MORE THAN PINK Walk
📍 Komen Tulsa Race for the Cure
📍 Komen Wisconsin MORE THAN PINK Walk
📍 Komen Orange County MORE THAN PINK Walk
📍 Komen Indianapolis MORE THAN PINK Walk
📍 Komen Houston Race for the Cure
📍 Komen Central Jersey MTPW

This partnership combines Natera’s leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen’s global advocacy and patient support network.

Join us on the ground in cities across the nation as we walk, fundraise, and show up for everyone impacted by breast cancer. 🎗️

10/02/2026

By combining standard sequencing with advanced long-read technology, our Zenith™ platform provides deeper insights to help reach a definitive diagnosis for patients with specific variants.

In this clip, Dr. Danny Miller of Seattle Children’s Hospital and University of Washington explains why this matters: When a DNA repeat is longer than the read itself, you can't measure how long it is. You can also miss sequence interruptions entirely — and they can be clinically important.

Long-read sequencing solves this problem because the reads are simply long enough to span the entire repeat. This means you can accurately measure the repeat length and detect those interruptions that short reads might miss.

For the many pediatric neurogenetic conditions that involve tandem repeat expansions, this makes a real difference.

Zenith™ Genomics for rare disease Zenith™ genomics provides the most complete analysis for patients suspected of rare disease. Early testing is crucial to stop the diagnostic odyssey, guide early intervention, and provide families with the prognostic clarity they need. The Zenith™ platform is ...

10/01/2026

Our CEO, Steve Chapman, recently sat down with Jonathan Palmer, host of the podcast, Vanguards of Healthcare by Bloomberg Intelligence, for a thoughtful discussion on Natera. Steve was one of Natera’s earliest employees, when the company was much smaller and focused solely on women’s health. Since that time, Natera has branched into organ health, oncology, and rare disease, becoming a precision medicine leader. As noted in the podcast summary:

“‘Clinical data is the key to being successful in diagnostics,’ Steve Chapman, CEO of Natera, tells Bloomberg Intelligence analyst Jonathan Palmer as he explains how an early bet on evidence helped turn a small genetic-testing company into a broad diagnostics platform. Chapman traces Signatera™ from a side project into a leading minimal residual disease (MRD) test and details Natera’s nearly $1 billion R&D investment to push into genome-based testing, early cancer detection and new indications. The conversation also explores the next layer of value from Natera’s platform — millions of longitudinal data points, AI-enhanced test results and patient experiences, more efficient biopharma trials and the potential to use neoantigen prediction algorithms to support personalized cancer vaccines.”

Listen in for more. https://ow.ly/b24f50ZTxMr